Tagrisso is an anti-cancer drug owned by Astrazeneca. It contains the active ingredient osimertinib mesylate and comes in tablet form for oral administration. Tagrisso first received market authorization on November 13, 2015.
The generic version of Tagrisso can become available after January 2, 2035. This is because the expiration date for the last relevant patent (US10183020 titled 'Pharmaceutical compositions comprising AZD9291') is on that date. Other patents protecting Tagrisso includes US9732058, US11524951, and US8946235 expiring no later than August 8, 2032.
Tagrisso is mainly used in the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) who have progressed on or after EGFR TKI therapy. It is also used for patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21L858R mutations. Further, it can be an adjuvant therapy after tumor resection in patients with NSCLC whose tumors harbor the same EGFR mutations.
Tagrisso, protected by 4 patents, is shielded from generic competition until at least January 2, 2035, when the last of its protecting patents (US10183020) expires. The Tagrisso generic is, therefore, potentially available from 2035. Below are the details of the patent: